WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has reported its financial results for the fourth quarter and ...

and we also anticipate advancing VP-102 (YCANTH) into a Phase 3 clinical trial for the treatment of common warts as early as mid-2025. With a leaner and more capital-efficient operating model now in ...

Verrica’s product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with ...

and we also anticipate advancing VP-102 (YCANTH) into a Phase 3 clinical trial for the treatment of common warts as early as mid-2025. With a leaner and more capital-efficient operating model now ...